| abstract |
Described herein is the combination of (S) -2- (5 - ((3-ethoxy-pyridin-2-yl) oxy) pyridin-3-yl) -N- (tetrahydrofuran-3-yl) pyrimidine-5 -carboxamide, or a pharmaceutically acceptable salt thereof, and 4- (4- (1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro- [indazole-5,4'-piperidine] -1 acid '-carbonyl) -6-methoxypyridin-2-yl) benzoic acid, or pharmaceutically acceptable salt thereof, for the treatment of diseases, including nonalcoholic steatohepatitis (NASH), in mammals. |